Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 14
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 14

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderABVC · 47
Strongest available pathGeron · +8.8%
Widest latest marginEmergent BioSolutions · 7.1%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ABVC · Nasdaq

ABVC

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1990Fremont$22.9M market cap
View full Companies Radar profile
47Cautious
Snapshot price$0.86as of page date
Monthly-close return-96.3%five-year window
FY2025 revenue$0.00BABVC BIOPHARMA, INC.
Net margin-2671.8%FY2025
Prism attention2.6%share across these five
Filing track recordRevenue, USD billions
-16.8%
$0$0.0B$0.0B$0.1BFY2021: $0.000BFY2022: $0.001BFY2023: $0.000BFY2024: $0.050BFY2025: $0.000B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021, FY2022, FY2023 · CAGR -4.5%
52-week position6% through range
$0.71$3.40
News mentions258
Community mentions0partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position10/100
Capital-event signal44/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 4 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2EQ · Nasdaq

Equillium

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2017San Diego, California$143.9M market cap
View full Companies Radar profile
47Cautious
Snapshot price$2.27as of page date
Monthly-close return-66.7%five-year window
FY2025 revenue$0.04BEquillium, Inc.
Net margin-54.5%FY2025
P/E snapshot-9.7xone ratio, not a verdict
Prism attention4.7%share across these five
Filing track recordRevenue, USD billions
+160.8%
$0$0.0B$0.0B$0.0BFY2022: $0.016BFY2023: $0.036BFY2024: $0.041BFY2025: $0.041B2022202320242025
FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 37.6%
52-week position54% through range
$0.76$3.54
News mentions473
Community mentions0partial coverage
U.S.-scope patents33
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal68/100
Management stability90/100
Market position11/100
Capital-event signal43/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3GERN · Nasdaq

Geron

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1992Menlo Park, California$957.3M market cap
View full Companies Radar profile
47Cautious
Snapshot price$1.49as of page date
Monthly-close return+8.8%five-year window
FY2023 revenue$0.00BGERON CORP
Net margin-77690.7%FY2023
P/E snapshot37.2xone ratio, not a verdict
Prism attention26.6%share across these five
Filing track recordRevenue, USD billions
-48.5%
$0$0.0B$0.0B$0.0BFY2019: $0.000BFY2020: $0.000BFY2021: $0.001BFY2022: $0.001BFY2023: $0.000B20192020202120222023
FY2019–FY2023 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -15.3%
52-week position46% through range
$1.04$2.01
News mentions2.6K
Community mentions416partial coverage
U.S.-scope patents1584
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal57/100
Management stability90/100
Market position0/100
Capital-event signal75/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 9 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4NKTR · Nasdaq

Nektar

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1990Wilmington$2.44B market cap
View full Companies Radar profile
47Cautious
Snapshot price$71.38as of page date
Monthly-close return-73.5%five-year window
FY2025 revenue$0.06BNEKTAR THERAPEUTICS
Net margin-297.1%FY2025
P/E snapshot-6.6xone ratio, not a verdict
Prism attention35.9%share across these five
Filing track recordRevenue, USD billions
-45.8%
$0$0.0B$0.1B$0.1BFY2021: $0.102BFY2022: $0.092BFY2023: $0.090BFY2024: $0.098BFY2025: $0.055B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.2%
52-week position54% through range
$27.87$109.0
News mentions3.6K
Community mentions0partial coverage
U.S.-scope patents2536
Prism Insights

What sits behind the readiness signal

Observed risk 6/100higher means more observed risk
Earnings signal54/100
Management stability90/100
Market position8/100
Capital-event signal81/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 6 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5EBS · NYSE

Emergent BioSolutions

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Gaithersburg, Maryland$312.8M market cap
View full Companies Radar profile
46Cautious
Snapshot price$6.10as of page date
Monthly-close return-87.8%five-year window
FY2025 revenue$0.74BEmergent BioSolutions Inc.
Net margin7.1%FY2025
P/E snapshot5.8xone ratio, not a verdict
Prism attention30.2%share across these five
Filing track recordRevenue, USD billions
-32.8%
$0$0.5B$1.0B$1.6BFY2019: $1.106BFY2020: $1.555BFY2022: $1.079BFY2023: $1.023BFY2025: $0.743B20192020202220232025
FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2022, FY2023 · CAGR -9.5%
52-week position18% through range
$4.36$14.06
News mentions3.0K
Community mentions0partial coverage
U.S.-scope patents30
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal30/100
Management stability90/100
Market position48/100
Capital-event signal61/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 23 asset-acquisition events and 47 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Geron
+8.8%
Equillium
-66.7%
Nektar
-73.5%
Emergent BioSolutions
-87.8%
ABVC
-96.3%

Latest revenue

USD billions, official filing scope shown on each company card.

Emergent BioSolutions
$0.74B
Nektar
$0.06B
Equillium
$0.04B
ABVC
$0.00B
Geron
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Emergent BioSolutions
7.1%
Equillium
-54.5%
Nektar
-297.1%
ABVC
-2671.8%
Geron
-77690.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Nektar
35.9%
Emergent BioSolutions
30.2%
Geron
26.6%
Equillium
4.7%
ABVC
2.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Nektar leads the conversation

It holds 35.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.06B.

Price path

Geron leads the available price paths

Its monthly-close return is +8.8% for the five-year window. At the other end, ABVC is -96.3% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Emergent BioSolutions has the widest latest margin

Its FY2025 net margin is 7.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Equillium shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -9.7x while its five-year window price return is -66.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · GERN

Geron

2,650available Prism news records

Prism top themes

Legal, arbitration & regulatory
107
Price action & investor response
93
Earnings & financial performance
62
Leadership & governance
40
Capital allocation & transactions
15

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-71.7%207 latest 12m vs 731 prior 12m
2024-01: 11 mentions2024-02: 29 mentions2024-03: 60 mentions2024-04: 20 mentions2024-05: 55 mentions2024-06: 42 mentions2024-07: 21 mentions2024-08: 12 mentions2024-09: 23 mentions2024-10: 14 mentions2024-11: 30 mentions2024-12: 23 mentions2025-01: 12 mentions2025-02: 412 mentions2025-03: 73 mentions2025-04: 77 mentions2025-05: 21 mentions2025-06: 13 mentions2025-07: 4 mentions2025-08: 19 mentions2025-09: 18 mentions2025-10: 14 mentions2025-11: 20 mentions2025-12: 16 mentions2026-01: 20 mentions2026-02: 19 mentions2026-03: 15 mentions2026-04: 32 mentions2026-05: 28 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

83.7% positive+7.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 36class action securities litigation 28stock price 24stem cell banking 20stock surge 19minority shareholder protections 17earnings report 14gene therapy rare diseases 14

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-12 · trend and themes shown through 2026-06
Areas of research · NKTR

Nektar

3,578available Prism news records

Prism top themes

Price action & investor response
161
Legal, arbitration & regulatory
71
Capital allocation & transactions
34
Earnings & financial performance
29
Leadership & governance
22

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+69.3%921 latest 12m vs 544 prior 12m
2024-01: 6 mentions2024-02: 13 mentions2024-03: 45 mentions2024-04: 16 mentions2024-05: 30 mentions2024-06: 9 mentions2024-07: 10 mentions2024-08: 17 mentions2024-09: 11 mentions2024-10: 13 mentions2024-11: 26 mentions2024-12: 12 mentions2025-01: 23 mentions2025-02: 314 mentions2025-03: 36 mentions2025-04: 15 mentions2025-05: 21 mentions2025-06: 46 mentions2025-07: 20 mentions2025-08: 24 mentions2025-09: 31 mentions2025-10: 20 mentions2025-11: 32 mentions2025-12: 36 mentions2026-01: 535 mentions2026-02: 60 mentions2026-03: 39 mentions2026-04: 86 mentions2026-05: 34 mentions2026-06: 4 mentions2024-012026-06

Machine-classified coverage tone

93.4% positive+4.2 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

prog rock epics 518genre-defying rock 511digital rock production 510epic rock compositions 510conceptual rock albums 510avant-garde rock 510symphonic rock pieces 119extended rock compositions 118

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-11 · trend and themes shown through 2026-06
Areas of research · EBS

Emergent BioSolutions

3,015available Prism news records

Prism top themes

Legal, arbitration & regulatory
276
Price action & investor response
34
Earnings & financial performance
32
Capital allocation & transactions
29
Leadership & governance
23

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.8%414 latest 12m vs 384 prior 12m
2024-01: 13 mentions2024-02: 13 mentions2024-03: 19 mentions2024-04: 20 mentions2024-05: 20 mentions2024-06: 12 mentions2024-07: 27 mentions2024-08: 61 mentions2024-09: 38 mentions2024-10: 12 mentions2024-11: 13 mentions2024-12: 7 mentions2025-01: 20 mentions2025-02: 106 mentions2025-03: 56 mentions2025-04: 18 mentions2025-05: 16 mentions2025-06: 10 mentions2025-07: 22 mentions2025-08: 11 mentions2025-09: 17 mentions2025-10: 14 mentions2025-11: 12 mentions2025-12: 7 mentions2026-01: 35 mentions2026-02: 220 mentions2026-03: 11 mentions2026-04: 35 mentions2026-05: 29 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

68.8% positive-22.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine formulation 48dispute resolution 45ftc enforcement actions 39telemarketing regulations 39false claims defense 39viral vector vaccines 35vaccine trials 28arbitral tribunal 26

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-11–2026-06-03 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

GERN

Geron

416 mentions
Stock and valuation
144
Products, pricing and logistics
37
Other company context
4
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 416 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ABVC

ABVC

through 2026-03-03
Earnings releases 8Business contracts 3Regulatory 3Asset acquisitions 2Leadership changes 2
  1. Earnings releases

    ABVC BioPharma reported a 179% year-over-year increase in total assets to $21.06 million for the fiscal year ended December 31, 2025, according to its recently filed Annual Report on Form 10-K.

  2. Business contracts

    ABVC BioPharma, Inc. (NASDAQ:ABVC) shares are trading higher Tuesday after the company announced it has entered into a global licensing agreement with ForSeeCon Eye Corporation for the company’s ophthalmology pipeline.

  3. Asset acquisitions

    ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EQ

Equillium

through 2025-11-14
Earnings releases 8Company announcements 1Leadership changes 1
  1. Earnings releases

    Net loss for the third quarter of 2025 was $4.2 million, or $(0.06) per basic and diluted share, compared with a net loss of $7,000, or $(0.00) per basic and diluted share for the same period in 2024.

  2. Company announcements

    Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.

  3. Leadership changes

    Equillium, Inc. has announced the appointment of Penny Tom as its new principal accounting officer, succeeding Jason Keyes who remains the CFO.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GERN

Geron

through 2025-11-06
Lawsuits 16Leadership changes 14Earnings releases 12Regulatory 5Listing / IPO 3
  1. Earnings releases

    Geron Corporation ((GERN)) has held its Q3 earnings call.

  2. Leadership changes

    Mr. Tyavanagimatt is expected to join Geron on October 20, 2025.

  3. Lawsuits

    SOURCE The Gross Law Firm

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NKTR

Nektar

through 2026-04-23
Earnings releases 28Listing / IPO 8Leadership changes 6Company announcements 4Asset acquisitions 3
  1. Listing / IPO

    Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

  2. Lawsuits

    The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics

  3. Earnings releases

    Net loss for the fourth quarter of 2025 was $36.1 million or $1.78 basic and diluted net loss per share as compared to net income of $7.3 million or $0.521 basic and diluted earnings per share in the fourth quarter of 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EBS

Emergent BioSolutions

through 2026-04-30
Asset acquisitions 23Earnings releases 22Company announcements 17Business contracts 11Leadership changes 11
  1. Earnings releases

    First Quarter 2026 Total Revenues of $156.1 million

  2. Leadership changes

    Emergent BioSolutions Inc. (NYSE: EBS ) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026.

  3. Business contracts

    Meanwhile, Bora recently acquired its first sterile manufacturing facility in Baltimore through a 2024 agreement with Emergent BioSolutions.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 66–73. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Emergent BioSolutions and Emergent BioSolutions

Emergent BioSolutions has the largest displayed latest revenue at $0.74B; Emergent BioSolutions has the widest displayed latest margin at 7.1%.

Open Emergent BioSolutions in Companies Radar
Comparisons
Anomalies

ABVC has the widest attention-readiness rank gap

It ranks #5 by measured news attention (2.6%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open ABVC in Companies Radar

Equillium shows a price-operating divergence to inspect

Its displayed filing-revenue change is +160.8% while its available monthly-close return is -66.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Equillium in Companies Radar
Explanations

Attention measures coverage volume, not quality

Nektar's 35.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Nektar in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open ABVC's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 47/100 score.

Open ABVC in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon